Abstract
HER-2 overexpression does not guarantee response to HER2-targeting drugs such as trastuzumab, which is cardiotoxic and expensive, so early detection of response status is crucial. Factors influencing [18F]FDG incorporation in the timeframe of cell signalling down-regulation subsequent to trastuzumab treatment are investigated to provide a better understanding of the relationship between growth response and modulation of [18F]FDG incorporation. HER-2-overexpressing breast tumour cell lines, MDA-MB-453, SKBr3 and BT474 and MDA-MB-468 (HER2 non-over-expressor) were treated with trastuzumab (4 h) and probed for AKT, pAKT, ERK1/2, pERK1/2 and HIF-1α to determine early signalling pathway inhibitory effects of trastuzumab. Cells incubated with trastuzumab and/or PI3K inhibitor LY294002 and ERK1/2 inhibitor U0126 and glucose transport and [18F]FDG incorporation measured. Cell lines expressed AKT, pAKT, ERK1/2 and pERK1/2 but not HIF-1α. Trastuzumab treatment decreased pAkt but not pERK1/2 levels. Trastuzumab did not further inhibit AKT when maximally inhibited with LY294002. Treatment with LY294002 and trastuzumab for 4 h decreased [18F]FDG incorporation in BT474 and MDA-MB-453 but not SKBr3 cells. LY294002 inhibited glucose transport by each cell line, but the glucose transport rate was tenfold higher by SKBr3 cells than BT474 and MDA-MB-453 cells. AKT-induced uptake of [18F]FDG was found to be HIF-1α independent in breast cancer cell lines. AKT inhibition level and tumour cell glucose transport rate can influence whether or not PI3K inhibitors affect [18F]FDG incorporation which may account for the variation in preclinical and clinical findings associated with [18F]FDG-PET in response to trastuzumab and other HER-2 targeting drugs.
Similar content being viewed by others
References
www.cancer.org/cancer/breastcancer/overviewguide/breast-cancer-overview-key-statistics. Accessed 15 Dec 2013
Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signalling pathway in cancer. Curr Opin Genet Dev 20:87–90
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084–6091
Schulze WX, Deng L, Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1:8
Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS (2004) The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 91:1190–1194
Nahta R, Esteva FJ (2006) HER2 therapy—molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 344:783–792
Evangelista L, Rubello D, Saladini G (2012) Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients? Eur J Nucl Med Mol Imaging 39:446–449
Maynard J, Ricketts SA, Gendrin C, Dudley P, Davies BR (2013) 2-Deoxy-2-[18F]fluoro-d-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363. Mol Imaging Biol 15:476–485
Kelly CJ, Hussien K, Muschel RJ (2012) 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition. Nucl Med Biol 39:986–992
Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ (2008) Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 10:745–756
Shah C, Miller TW, Wyatt SK et al (2009) Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 15:4712–4719
Janjigian YY, Viola-Villegas N, Holland JP et al (2013) Monitoring afatinib treatment in HER2-positive gastric cancer with F-18-FDG and Zr-89-trastuzumab PET. J Nucl Med 54:936–943
Flores LG, Yeh HH, Soghomonyan S et al (2013) Monitoring therapy with MEK inhibitor U0126 in a novel wilms tumor model in Wt1 knockout Igf2 transgenic mice using F-18-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth. Mol Imaging Biol 15:175–185
Cheyne RW, Trembleau L, McLaughlin AC, Smith TAD (2011) Changes in 2-fluoro-2-deoxy-d-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab. Nucl Med Biol 38:339–346
Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M (2007) Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5:195–201
Smith TAD, Zanda M, Fleming IN (2013) Hypoxia stimulates 18F-fluorodeoxyglucose uptake in breast cancer cells via hypoxia induced factors-1 and AMP-activated protein kinase. Nucl Med Biol 40:858–864
Rusnak DW, Alligood KJ, Mullin RJ et al (2007) Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) proteins expression levels and response to lapatinab (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40:580–594
Powis G, Ihle N, Kirkpatrick DL (2006) Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res 12:2964–2966
Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95–105
Lambert CM, Roy M, Robitaille GA, Richard DE, Bonnet S (2010) HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism. Cell Prolif 88:196–204
Fan YJ, Dickman KG, Zong WX (2010) Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 285:7324–7333
Elstrom RL, Bauer DE, Buzzai M et al (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892–3899
Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL (2013) Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res 19:610–619
Normanno N, Campiglio M, De Luca A et al (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65–72
Nguyen QD, Perumal M, Waldman TA, Aboagye EO (2011) Glucose metabolism measured by [F-18]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Transl Oncol 4:231–238
Chan CH, Li CF, Yang WL et al (2012) The Skp2-SCF E3 ligase regulates akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149:1098–1111
Palaskas N, Larson SM, Schultz N et al (2011) F-18-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res 71:5164–5174
Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB (2003) Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23:7315–7328
Wieman HL, Wofford JA, Rathmell JC (2007) Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 18:1437–1446
Kawada K, Murakami K, Sato T et al (2007) Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol 37:44–48
McLarty K, Fasih A, Scollard DA et al (2009) F-18-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. J Nucl Med 50:1848–1856
Smith TAD, Appleyard MVCL, Sharp S, Fleming IN, Murray K, Thompson AM (2013) Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [F-18]-FDG incorporation and changes in P-31-NMR-detectable phosphomonoesters. Cancer Chemother Pharmacol 71:473–480
Davies BR, Greenwood H, Dudley P et al (2012) Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11:873–887
Zundel W, Schindler C, Haas K et al (2000) Loss of PTED facilitates HIF-1-mediated gene expression. Genes Dev 14:391–396
Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia inducible factor-1 alpha expression by the epidermal growth factor/phosphatidylinositol-3-kinase/PTEN/FRAP pathway in human prostate cancer cells; implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545
Burrows N, Babur M, Resch J et al (2011) GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by Targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1 alpha (HIF-1 alpha) pathways. J Clin Endocrinol Metab 96:E1934–E1943
Majumder PK, Febbo PG, Bikoff R et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594–601
Bhaskar PT, Nogueira V, Patra KC, Jeon SM, Park Y, Robey RB, Hay N (2009) mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3 beta inhibition. Mol Cell Biol 29:5136–5147
Jones A, Fujiyama C, Blanche C et al (2001) Relationship of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 α and hypoxia-inducible factor-2 α in human bladder tumors and cell line. Clin Cancer Res 7:1263–1272
Acknowledgment
The work was funded by the University of Aberdeen and Friends of Anchor. We thank Dr Iain Brown, University of Aberdeen, for the generous gift of the anti-pHER2 antibody
Disclosure
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fleming, I.N., Andriu, A. & Smith, T.A.D. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α. Breast Cancer Res Treat 144, 241–248 (2014). https://doi.org/10.1007/s10549-014-2858-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-014-2858-1